Data-driven drug strategy

Over the last 30 years, Equinox Group has provided commercial strategy consulting to biopharmaceutical firms at all stages of R&D to ensure they are set up for success. Our proprietary and rigorous modeling techniques are fast, flexible, and cost-effective.

 
 
 
 

Want to know how Equinox Group views recent launches and assets in the pipeline? Check out our blog posts.

Our Take Blog
Enhertu regimen Figure (1).jpg
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Enhertu is poised to dominate first-line HER2+ breast cancer
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Read More →
Enhertu, breast cancer, AstraZeneca, Daiichi-Sankyo
Xolair-Figure JPG.jpg
Xolair, Food allergy, Genentech, Novartis
Xolair for food allergies: effective therapy at a high price
Xolair, Food allergy, Genentech, Novartis
Read More →
Xolair, Food allergy, Genentech, Novartis
Leqembi-Figure.jpg
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Monoclonal antibodies for Alzheimer’s disease: questionable clinical benefit at a high price
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Read More →
Leqembi, Aduhelm, donanemab, Alzheimer's Disease, Eisai, Biogen, Eli Lilly
Evrysdi-figure.jpg
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Evrysdi: A Potential Game-Changer for SMA Type 1 Patients
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Read More →
Zolgensma, Spinraza, Evrysdi, Biogen, Novartis, Roche, SMA Type 1, Spinal Muscular Atrophy
Cost Benefit Yescarta CAR T post.png
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
CAR-T Outlook
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Read More →
Yescarta, Breyanzi, Carvykti, DLBCL, Multiple Myeloma, Kite, Bristol Myers Squibb, Janssen
Risperidone-vs.-Ulatorant.jpg
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Prospects for ulotaront in schizophrenia
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Read More →
ulotaront, Sunovion, Lybalvi, schizophrenia, risperidone, Alkermes
Enhertu-vs.-Kadcyla.jpg
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Enhertu shows high clinical innovation in second-line metastatic breast cancer
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Read More →
Enhertu, Daiichi-Sankyo, AstraZeneca, Breast Cancer
Keytruda-and-Lenvima-Figure.jpg
Keytruda, Merck, Eisai, Lenvima, RCC
Weighing Efficacy vs. Tolerability: Lenvima + Keytruda in Advanced ccRCC
Keytruda, Merck, Eisai, Lenvima, RCC
Read More →
Keytruda, Merck, Eisai, Lenvima, RCC
amivantamab figure jpeg.jpg
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Rybrevant and Exkivity: two highly innovative new therapies to treat EGFR Exon 20 Insertion positive mNSCLC
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Read More →
Rybrevant, Exkivity, Janssen, Takeda, NSCLC
Capture3.JPG
Prioritizing Indications: An Analytical Framework
Read More →
drivers.png
Trodelvy, TNBC, Gilead
Trodelvy: A New Option for Later Lines TNBC
Trodelvy, TNBC, Gilead
Read More →
Trodelvy, TNBC, Gilead
Onco Drivers.PNG
Monjuvi, lenalidomide, DLBCL, Incyte
Monjuvi: Newest Blockbuster in Relapsed/Refractory DLBCL
Monjuvi, lenalidomide, DLBCL, Incyte
Read More →
Monjuvi, lenalidomide, DLBCL, Incyte
Two indications.PNG
Rozlytrek, Brain Mets, Xalkori, ROS1
Comparing Opportunity Across Subpopulations: Rozlytrek as a Case Study
Rozlytrek, Brain Mets, Xalkori, ROS1
Read More →
Rozlytrek, Brain Mets, Xalkori, ROS1
Drivers.JPG
Melanoma, Pfizer, Braftovi, Mektovi
Pfizer Combo Gains an Edge in BRAF+ Melanoma
Melanoma, Pfizer, Braftovi, Mektovi
Read More →
Melanoma, Pfizer, Braftovi, Mektovi
Drivers.JPG
Trikafta, Cystic Fybrosis, Vertex
Trikafta: A Major Step Forward for Cystic Fibrosis Patients
Trikafta, Cystic Fybrosis, Vertex
Read More →
Trikafta, Cystic Fybrosis, Vertex
A Reliable Predictor of NICE Recommendation
NICE
A Reliable Predictor of NICE Recommendation
NICE
Read More →
NICE
Table.JPG
Brukinsa, MCL, Mantle Cell Lymphoma
Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma
Brukinsa, MCL, Mantle Cell Lymphoma
Read More →
Brukinsa, MCL, Mantle Cell Lymphoma
Drivers website.JPG
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Lynparza: Expanding into Prostate Cancer
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Read More →
Xtandi, Zytiga, HRRm, Lynparza, prostate cancer
Bubble chart.JPG
Keytruda, drug pricing, NSCLC
Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda
Keytruda, drug pricing, NSCLC
Read More →
Keytruda, drug pricing, NSCLC
drivers correct.JPG
Enhertu, breast cancer, AstraZeneca, HER2+
Enhertu: A New Leader in Later-Line Breast Cancer
Enhertu, breast cancer, AstraZeneca, HER2+
Read More →
Enhertu, breast cancer, AstraZeneca, HER2+
Zejula Updated.JPG
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
PARP Inhibitors: Promise in New Maintenance Indications
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
Read More →
Zejula, Lynparza, BRCA-mutated, maintenance therapy, ovarian, pancreatic
now onco.png
Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model
Read More →
Capture.JPG
Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC
Read More →
Capture.JPG
drug pricing
Pricing a new oncology agent across multiple indications
drug pricing
Read More →
drug pricing
Drivers for Calquence.PNG
Calquence: The price is right
Read More →
radicava, ALS, edaravone, riluzole
Radicava: Not Innovative Enough to Sustain Strong Start
radicava, ALS, edaravone, riluzole
Read More →
radicava, ALS, edaravone, riluzole
dfsdf.png
How to Price an Oncology Drug
Read More →
Capture.JPG
Hemlibra, Hemophilia A, Advate, emicizumab
Hemlibra: A Strong Leader in Hemophilia A
Hemlibra, Hemophilia A, Advate, emicizumab
Read More →
Hemlibra, Hemophilia A, Advate, emicizumab
Capture.JPG
Oral semaglutide: A game changer in type 2 diabetes
Read More →
Tymlos, osteoporosis, ACTIVE, pharma
Tymlos: A new force in the osteoporosis market
Tymlos, osteoporosis, ACTIVE, pharma
Read More →
Tymlos, osteoporosis, ACTIVE, pharma